Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Heron Therapeutics Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
HRTX
Nasdaq
2834
https://www.herontx.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Heron Therapeutics Inc
Heron Therapeutics Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference
- Mar 28th, 2024 8:05 pm
Heron Therapeutics Full Year 2023 Earnings: Beats Expectations
- Mar 14th, 2024 10:51 am
Heron Therapeutics, Inc. (NASDAQ:HRTX) Q4 2023 Earnings Call Transcript
- Mar 13th, 2024 1:19 pm
Q4 2023 Heron Therapeutics Inc Earnings Call
- Mar 13th, 2024 11:04 am
Compared to Estimates, Heron Therapeutics (HRTX) Q4 Earnings: A Look at Key Metrics
- Mar 12th, 2024 10:00 pm
Heron Therapeutics Inc (HRTX) Exceeds Full-Year Revenue Guidance for 2023
- Mar 12th, 2024 9:33 pm
Heron Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Updates
- Mar 12th, 2024 8:05 pm
Oncternal Therapeutics (ONCT) Reports Q4 Loss, Tops Revenue Estimates
- Mar 7th, 2024 10:35 pm
Curious about Heron Therapeutics (HRTX) Q4 Performance? Explore Wall Street Estimates for Key Metrics
- Mar 7th, 2024 2:15 pm
Zacks Industry Outlook Highlights United Therapeutics, Esperion Therapeutics., Heron Therapeutics, Lyra Therapeutics and Aldeyra Therapeutics
- Mar 1st, 2024 2:45 pm
5 Small Drug Stocks to Buy From a Rebounding Industry
- Feb 29th, 2024 1:53 pm
Heron Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results On Tuesday, March 12, 2024
- Feb 28th, 2024 1:00 pm
12 Best Rising Penny Stocks To Buy
- Feb 23rd, 2024 4:56 pm
Investors in Heron Therapeutics (NASDAQ:HRTX) from five years ago are still down 90%, even after 23% gain this past week
- Feb 16th, 2024 10:09 am
Ocular Therapeutix (OCUL) Surges 12.9%: Is This an Indication of Further Gains?
- Feb 12th, 2024 11:27 am
All You Need to Know About Heron Therapeutics (HRTX) Rating Upgrade to Strong Buy
- Feb 6th, 2024 5:00 pm
Heron (HRTX) Gains 19% on FDA Nod for Zynrelef Label Expansion
- Jan 25th, 2024 11:44 am
Heron Therapeutics' Non-Opioid, Post-Operative Pain Drug Approved For Use In Additional Orthopedic, Soft Tissue Procedures - FDA Gives Nod
- Jan 24th, 2024 6:47 pm
Heron Therapeutics Announces FDA Approval of ZYNRELEF® Indication Expansion to Include Additional Orthopedic and Soft Tissue Procedures
- Jan 24th, 2024 1:00 am
Heron Therapeutics, Inc. (NASDAQ:HRTX) is largely controlled by institutional shareholders who own 52% of the company
- Jan 22nd, 2024 11:16 am
Scroll